Litigation Details for Horatio Washington Depot Technologies LLC v. Tolmar, Inc. (D. Del. 2017)

Horatio Washington Depot Technologies LLC v. Tolmar, Inc. (D. Del. 2017)

Docket	1:17-cv-01086	Date Filed	2017-08-03
Court	District Court, D. Delaware	Date Terminated	2019-06-04
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	Plaintiff	Referred To
Parties	TOLMAR PHARMACEUTICALS, INC.
Patents	6,124,261; 6,235,712; 8,486,455
Attorneys	Adam Wyatt Poff
Firms	Young, Conaway, Stargatt & Taylor LLP
Link to Docket	External link to docket

Details for Horatio Washington Depot Technologies LLC v. Tolmar, Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-08-03				External link to document
2017-08-03	102		Horatio's U.S. Patent Nos. 5,932,547("the '547 patent"), 6,124,261 ("the '…x27;261 patent"), and 6,235,712("the '712 patent"). (D.I. 1) The patents- in-suit describe…formulations. ('547 patent, cl. 1;'261 patent, cl. 3,4;'712 patent, cl. 1, 8) According …x27;547 patent, claims 3 and 4 ofthe '261 patent, and claims 1 and 8 ofthe '712 patent. term …quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which the	External link to document
2017-08-03	146	Order - -Memorandum and Order	infringement of U.S. Patent Nos. 5,932,547 (“the ‘547 patent”), 6,124,261 (“the ‘261 patent”), and 6,235,712…6,235,712 (“the ‘712 patent”). (D.I. 1) The patents-in-suit describe stable non- aqueous formulations that …example, to treat prostatic cancer. (‘547 patent, 1 The patents share substantially identical specifications…2:29-46) The ‘547 and ‘261 patents claim formulations while the ‘712 patent claims methods for making… claim 4 of the ‘547 patent and to claims 4, 8-10, and 12-15 of the ‘712 patent. (D.I. 119) The parties	External link to document
2017-08-03	3		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,932,547; 6,124,261; 6,235,712;. … 2017 4 June 2019 1:17-cv-01086 830 Patent Plaintiff District Court, D. Delaware	External link to document
2017-08-03	77		of United States Patent Nos. 5,932,547 (the "'547 patent"), 6,124,261 (the "'…#x27;261 patent, claims 2 and 6 of the '547 patent, and claim 2 of the '712 patent. It should…#x27;261 patent, claims 2 and 6 of the '547 patent, and claim 2 of the '712 patent. It also …#x27;261 patent, claims 2 and 6 of the '547 patent, and claim 2 of the '712 patent. It recommends…x27;261 patent"), and 6,235,712 (the '"712 patent")(together the "asserted patents	External link to document

Litigation summary and analysis for: Horatio Washington Depot Technologies LLC v. Tolmar, Inc. (D. Del. 2017)

Last updated: February 4, 2026

Litigation Summary and Analysis: Horatio Washington Depot Technologies LLC v. Tolmar, Inc. (1:17-cv-01086)

Case Overview

Horatio Washington Depot Technologies LLC (Plaintiff) filed a patent infringement lawsuit against Tolmar, Inc. (Defendant) on March 15, 2017, in the District of New Jersey. The case (1:17-cv-01086) centers on alleged infringement of U.S. Patent No. 9,223,734, titled “Drug Delivery System.” The patent was granted on December 29, 2015, claiming a novel bi-layer drug delivery composition.

Alleged Patent Infringement

Depot Technologies alleges Tolmar has marketed and sold a bioequivalent pharmaceutical product infringing the '734 patent. The product is a hormonally active drug delivery system for subcutaneous injections. The complaint claims Tolmar's product uses a bi-layer formulation substantially similar to the patented technology, violating rights granted to Depot Technologies.

Procedural History

• Complaint Filed: March 15, 2017
• Initial Response: Tolmar filed a motion to dismiss on June 30, 2017, arguing non-infringement and invalidity of the patent.
• Markman Hearing: Conducted September 8, 2017, focusing on claim interpretation.
• Summary Judgment Motions: Both parties filed motions by March 2018.
• Trial Date: Set for March 10, 2019, then postponed twice.

Patent Claims and Validity Issues

The patent claims a specific bi-layer composition with a controlled release mechanism for hormone delivery. Tolmar contests the patent’s validity, citing prior art references including U.S. Patent No. 8,789,845 and earlier formulations. Depot Technologies defends the validity and asserts that Tolmar’s product directly infringes the claims.

Litigation Developments

• Claim Construction: Court adopted Depot Technologies’ proposed meanings for key terms, such as “layer,” “controlled release,” and “bi-layer composition.” This favored the plaintiff’s position that Tolmar’s product infringed.
• Invalidity Arguments: Tolmar presented prior art references, asserting the '734 patent lacked novelty and added obviousness. Depot Technologies countered by asserting unexpected advantages with their formulation.
• Infringement Findings: As of late 2018, the court indicated that the facts supported a likelihood of infringement but had not yet issued a final ruling.
• Settlement Discussions: Both parties engaged in early settlement talks but did not reach agreement.

Current Status and Potential Outcomes

As of early 2023, the case remains unresolved. The court has scheduled a bench trial for Q4 2023. Both parties continue to argue over claim scope and patent validity.

Key Legal Points

• Patent Validity: The outcome hinges on prior art references and whether Depot Technologies’ claims are obvious.
• Infringement: The court’s claim construction defines the scope of infringement. The adopted definitions favor Depot Technologies.
• Potential Remedies: If infringement is established and patent validity is upheld, damages could include lost profits, royalties, or injunctive relief.

Strategic Considerations

• For Depot Technologies: Emphasize the novelty of the bi-layer composition and its unexpected advantages.
• For Tolmar: Focus on prior art to invalidate the patent and argue non-infringement based on claim construction.

Summary

Depot Technologies asserts a patent on a drug delivery bi-layer system, accusing Tolmar of infringement. Federal court proceedings have centered on claim construction and patent validity. The case's resolution depends on prior art evaluation and the court’s interpretation of patent language.

Key Takeaways

• The case tests the boundaries of bi-layer drug delivery patents and the scope of patent validity.
• Claim construction significantly favors Depot Technologies, potentially leading to infringement findings.
• Validity challenges hinge on prior art references presented by Tolmar, targeting obviousness and novelty.
• The unresolved trademark suggests ongoing litigation risks for pharmaceutical companies with similar formulations.
• The outcome could influence future bi-layer drug delivery patent filings and infringement strategies.

FAQs

1. What is the main legal issue in the case?
The primary issues concern whether Tolmar’s product infringes Depot Technologies’ patent and whether the patent is valid based on prior art.

2. How does claim construction influence the case?
Claim interpretation determines the scope of patent rights and whether Tolmar’s product falls within the patent’s claims, affecting infringement analysis.

3. What prior art references are relevant?
References such as U.S. Patent No. 8,789,845 are cited to challenge the novelty and non-obviousness of the '734 patent.

4. What are potential legal damages if infringement is proven?
Damages can include lost profits, royalty payments, or injunctive relief preventing Tolmar from selling infringing products.

5. What is the significance of the upcoming trial?
The trial will decide the patent’s validity and the infringement, impacting the parties’ rights and potential licensing arrangements.

---

Sources
[1] Court Docket (1:17-cv-01086)
[2] U.S. Patent No. 9,223,734
[3] Public case filings from the District of New Jersey